Comparative Pharmacology
Head-to-head clinical analysis: NICORETTE versus NICOTINE POLACRILEX ORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICORETTE versus NICOTINE POLACRILEX ORAL.
NICORETTE vs NICOTINE POLACRILEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine acts as an agonist at nicotinic acetylcholine receptors, stimulating the release of neurotransmitters such as dopamine and norepinephrine, which reduces withdrawal symptoms and cravings associated with smoking cessation.
Nicotine polacrilex acts as a nicotinic acetylcholine receptor agonist, binding to α4β2 receptors in the ventral tegmental area and mediating dopamine release in the nucleus accumbens, which reduces withdrawal symptoms and cravings by providing a lower and slower peak of nicotine compared to smoking.
Nicotine replacement therapy. For smoking cessation, chewing gum: 2 mg or 4 mg piece chewed slowly for 30 minutes every 1-2 hours as needed, maximum 24 pieces/day. Transdermal patch: Apply one 7 mg, 14 mg, or 21 mg/24 hour patch daily. Lozenge: 2 mg or 4 mg lozenge dissolved in mouth every 1-2 hours, maximum 20 lozenges/day. Inhaler: 6-16 cartridges/day. Nasal spray: 1-2 doses/hour, maximum 40 doses/day. All routes: typical duration 8-12 weeks.
2 mg or 4 mg lozenge or gum as needed up to 20 lozenges or pieces of gum per day; typical dosing: 1 lozenge or piece of gum every 1-2 hours while awake, up to 12 per day. For smoking cessation, initial dose based on smoking habits: if first cigarette within 30 minutes of waking, use 4 mg; if >30 minutes, use 2 mg.
None Documented
None Documented
The terminal elimination half-life of nicotine is approximately 2 hours. This short half-life necessitates frequent dosing or continuous delivery to maintain therapeutic levels. Cotinine, the major metabolite, has a half-life of 15-20 hours.
The terminal elimination half-life of nicotine is approximately 2 hours (range 1-4 hours) after intravenous administration or smoking, but after polacrilex gum use, absorption is slower and half-life may be slightly prolonged due to continued absorption. Clinical context: short half-life necessitates frequent dosing to maintain levels for smoking cessation.
Nicotine is extensively metabolized in the liver, primarily to cotinine. Renal excretion accounts for 2-35% of nicotine elimination unchanged, depending on urine pH (acidic urine increases excretion). Biliary/fecal excretion is minimal (<5%). Total clearance is about 1 L/min, with renal clearance of about 100 mL/min.
Nicotine and its metabolites are primarily excreted renally. About 10-20% of nicotine is excreted unchanged in urine, with the remainder as metabolites, mainly cotinine. Urinary pH affects excretion; acidic urine increases clearance. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Smoking cessation aid
Smoking cessation aid